Current ADCs still display poor translation of their preclinical therapeutic window into the clinic, due to limiting off-target toxicity of the toxic payloads in humans. VERAXA has developed a glycan-engineering based bioconjugation platform utilizing most efficient bioorthogonal click chemistry. The hydrophilic click payload platform highly improves on the safety profile of VERAXA’s ADCs, where each component addresses a specific mechanism of off-target toxicity. In vivo evaluation of the ADC technology revealed a highly widened therapeutic window of VERAXA’s anti-HER2 ADCs, compared to Enhertu.